Kornimate/medical-research-clean huggingface dataset:
effects of power ball exercises in addition to routine physical therapy in patients with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the purpose for doing this study is to determine that whether use of power ball in form of resistance training will be effective in increasing grip strength in carpel tunnel syndrome patient and possible benefits of the regime as effective means of rehabilitation for wrist and hand injuries. moreover for increasing grip strength it can be used as an adjunct for physical therapy treatment.


Eligibility criteria:
inclusion criteria: 1. age group 45-60 years 2. both male and female 3. clinically diagnosed carpal tunnel syndrome 4. carpal tunnel syndrome for a duration of more than 02 months 5. tingling sensation and numbness over the dorsal surface of thumb, index, middle, and lateral 1/3rd of ring fingers 6. positive tinel's sign 7. positive phalen's maneuver exclusion criteria: 1. any previous trauma, fracture, subluxation, dislocation, surgery or bony abnormalities around wrist joint in the past 5 years. 2. symptomatic arthritis of wrist joint 3. cervical radiculopathy 4. corticosteroid injection within 3 months

Keywords: physical therapy median neuropathy power ball exercise carpal tunnel syndrome
study evaluating the safety and tolerability of ncx 4251 for the treatment of acute exacerbations of blepharitis

Conditions: Blepharitis

Summary: this is a multi-center, randomized, double-masked, placebo-controlled, phase 2 study evaluating the safety and tolerability of ncx 4251 (fluticasone propionate nanocrystal) ophthalmic suspension 0.1% qd and bid for the treatment of acute exacerbations of blepharitis. the study will be performed in two sequential dose escalating cohorts. the study is designed to select the dose(s) of ncx 4251 to advance into the next stage of development, and to assess the safety and tolerability of ncx 4251 ophthalmic suspension.


Eligibility criteria:
inclusion criteria: * history of blepharitis and meet qualifying criteria for an acute exacerbation of blepharitis in both eyes at screening and baseline/day 1 visits * have a qualifying best-corrected visual acuity exclusion criteria: * abnormality of the eyelids or lashes (other than blepharitis), or previous eyelid surgery * iop \> 21 mmhg at screening or baseline/day 1 visits * use of steroids in the past 30 days or retinoids in the past 12 months * uncontrolled systemic disease
study to evaluate the efficacy of gs-9131 functional monotherapy in human immunodeficiency virus (hiv)-1-infected adults failing a nucleos(t)ide reverse transcriptase inhibitor-containing regimen with nucleos(t)ide reverse transcriptase inhibitor resistant virus

Conditions: HIV-1-infection

Summary: the primary objective of this study is to evaluate the short-term antiviral potency of gs-9131 functional monotherapy compared to placebo-to-match (ptm) gs-9131, each administered once daily with the existing failing antiretroviral (arv) regimen as demonstrated by the proportion of participants achieving human immunodeficiency virus ribonucleic acid (hiv-1 rna) \> 0.5 log10 decreases from baseline after up to 14 days of therapy in hiv-1 positive, arv treatment experienced adult participants with nucleos(t)ide resistant virus. this is a two-part study. part 1 consists of three cohorts: 2 sentinel cohorts and 1 randomized cohort. eligible participants from part 1 will proceed to part 2 followed by an optional open-label extension.


Eligibility criteria:
key inclusion criteria: * plasma hiv-1 rna ≥ 500 copies/ml at screening visit * currently taking a failing arv regimen that contains 2 nrtis and a nnrti * no prior or current arv regimens containing integrase inhibitor (insti) or protease inhibitor (pi) * screening genotype must show at least the protocol defined resistance mutation profile key exclusion criteria: * active, serious infections (other than hiv-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to day 1 * participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial * use of an investigational drug other than the study drug * individuals with chronic hepatitis b virus (hbv) infection are not permitted to participate * active tuberculosis infection note: other protocol defined inclusion/ exclusion criteria may apply.
electrophysiologically guided pacing site selection study

Conditions: Sinus Arrhythmia; Atrial Fibrillation

Summary: this study is a long-term, prospective, and controlled evaluation of the incidence of persistent atrial fibrillation (af) in patients with severe intra-right atrial conduction delay paced with preventive algorithms at the interatrial septum (ias) versus right atrial appendage (raa).

the epass is a multicenter, prospective, randomized, and controlled study. prior to entering the study, the patient should be informed and provide a written consent. in addition, the patient should meet all selection criteria. the investigator has to check that all selection criteria are satisfied. then the patient undergoes pacemaker implantation, receiving a pacemaker model t70 or selection 9000 (or later version). patients eligible for the study are enrolled and submitted to the evaluation of intra-light atrial conduction delay before device implantation. besides, they are assigned to the group with severe ra conduction delay or with normal conduction delay. the randomization of the pacing site for both groups depends on the value of right atrial conduction delay, together with the associated diseases of the patients, sex and age. after implantation, a stabilization phase of 3-5 weeks is required to stabilize the leads: during this period the physician can optimize the device parameters. neither the data regarding af episodes nor cardioversion are collected. at the end of the stabilization phase the patient undergoes the 1st study follow-up and starts the monitoring period lasting 2 years. regular follow-ups and data collection are scheduled every 6 months.

Eligibility criteria:
inclusion criteria: * symptomatic sinus node dysfunction * more than 18 years old * signed informed consent exclusion criteria: * less than 18 years old * pregnancy * anamnestic transient ischemic attack (tia) or stroke * neoplastic or any other severe disease reducing life expectancy * heart surgery in the last 3 months * left atrial diameter \> 55mm, determined in the parasternal long-axis view (during either sinus rhythm or atrial fibrillation) * participation in other studies

Keywords: atrial fibrillation interatrial septum atrial pacing symptomatic sinus node dysfunction, pacemaker indication class i
the efficacy and safety of sirolimus for plastic bronchitis

Conditions: Plastic Bronchitis

Summary: there is no confirmed drug therapy for plastic bronchitis. the study wish to test the effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic bronchitis.

plastic bronchitis is a rare respiratory disorder characterized by formation of gelatinous or rigid cast of bronchial tree. confirmed drug therapy for plastic bronchitis is lacking. recently, part of plastic bronchitis has been found to have dysfunction of lymphatic circulation in the lung. pulmonary lymphatic perfusion syndrome (plps) is regarded as a major mechanism of lymphatic plastic bronchitis. sirolimus (rapamycin) has not been studied in plastic bronchitis, however, it has been shown effective in several lymphatic disorders, such as lymphangioleiomyomatosis, generalized lymphatic anomaly (gla) including lymphangiomatosis, etc. we wish to test the effectiveness of sirolimus in lymphatic plastic bronchitis.

Eligibility criteria:
inclusion criteria: * plastic bronchitis * pulmonary lymphatic perfusion syndrome demonstrated on 68ga-neb positron emission tomography (pet) exclusion criteria: * pregnancy and breastfeeding * severe cardiovascular, hepatic and renal dysfunction * allergy to sirolimus or 68ga-neb

Keywords: plastic bronchitis sirolimus
root canal disinfection: a comparison between techniques

Conditions: Endodontically Treated Teeth

Summary: caries disease is still the leading cause of severe tooth decay. since this can lead to tooth loss, it is important that appropriate treatment is advised to help prevent damage and maintain tooth health. faced with major coronary destruction, several times it becomes necessary to perform the endodontic treatment, aiming to maintain the element in the buccal cavity for longer. it is known that an excellent restorative treatment with poor endodontic treatment and vice versa has a direct impact on the (in) success of the treatment. in this context, the proper cleaning of the root canals is highlighted, aiming the removal of bacteria and toxins. there are several cleaning methods described in the literature, but it is not yet known which would be the most effective in the removal of these contaminants. in this double-blind randomized clinical trial, patients who need and meet the inclusion criteria will undergo endodontic treatment in two different root canal cleansing techniques (passive ultrasonic cleaning and cleaning with the xp endo device). patients will be monitored annually after finish your endodontic treatment to evaluate the periradicular repair and the quality of endodontic treatment.


Eligibility criteria:
inclusion criteria: * 18 years old or more; * good general healthy; * molars or premolar requiring endodontic treatment; * at least 20 teeth; exclusion criteria: * root fracture; * injury involving the furcation region * need to behave as a prosthetic abutment; * mobility greater than degree i;
an 8 week study of adults diagnosed with major depressive disorder

Conditions: Depressive Disorder, Major

Summary: a placebo controlled study evaluating efficacy, safety and tolerability of medication in patients with major depressive disorder (mdd)


Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder (mdd) * duration of current depressive episode 12 weeks - 24 months * patients can read and write at a level sufficient to provide a signed consent * if female, patients must be practicing an acceptable method of birth control exclusion criteria: * patients have other psychiatric disorders that would affect patient's response to treatment * patients have not responded to two or more adequate courses of antidepressant therapy * patients cannot be currently abusing illicit drugs or alcohol * patients are not currently receiving psychotherapy * patients have received electroconvulsive therapy within 6 months prior to screening * patients are pregnant or lactating

Keywords: gw353162, major depressive disorder, flexible
cervical priming before dilation & evacuation

Conditions: Abortion, Induced

Summary: the purpose of this study is to compare the efficacy of buccal misoprostol cervical priming to laminaria priming among women undergoing d\&e at 13-20 weeks gestation in the western cape province, south africa

as misoprostol is increasingly being used for cervical preparation, concerns about its use and about the proportion of women expelling the fetus prior to the d\&e and other side effects mean that rigorous data on possible advantages of osmotic dilators are needed. to address this gap in the literature, we propose to perform an rct comparing two methods of cervical preparation prior to d\&e: 1. misoprostol 400 mcg administered buccally approximately 3-6 hours prior to d\&e, repeated once 3 hours after the first dose (a modified version of the current protocol) 2. laminaria tents inserted into the cervix 18 to 24 hours prior to d\&e

Eligibility criteria:
inclusion criteria: * woman seeking top between 13 and 20 weeks gestation as determined by ultrasound * age 18 or greater * willingness to participate in randomized study * fluency in english, afrikaans or xhosa * ability to give informed consent * staying within one hour travel time of tygerberg hospital for the night prior to the d\&e * ability to be contacted by telephone exclusion criteria: * active cervicitis * multiple gestation * fetal demise confirmed by ultrasound examination * history of bleeding disorder or current anticoagulation therapy * allergy to misoprostol * currently breastfeeding and unwilling or unable to temporarily discard milk * more than one prior cesarean delivery

Keywords: abortion, induced laminaria misoprostol pregnancy trimester, second
mechanisms of resistance to amivantamab in patients with nsclc with egfr exon 20 insertion

Conditions: Non-small Cell Lung Cancer; EGFR Exon 20 Insertion Mutation

Summary: the goal of this prospective, interventional study is to evaluate the mechanisms of acquired resistance to amivantamab monotherapy in patients with advanced nsclc with egfr ins20. the main question it aims to answer is: what are the mechanisms of acquired resistance to amivantamab monotherapy in this population of patients ? how anticipate the efficacy of subsequent systemic therapies ? after this information session, the participant will be asked to sign the study informed consent. a blood samples (2\*10 ml on ethylenediaminetetraacetic acid (edta)) will be taken at time of disease progression and will be sent for central liquid biopsy ctdna analysis. if available, tumor tissue will also be sent for dna ngs analysis.

resamex is a prospective study evaluating the mechanisms of acquired resistance to amivantamab monotherapy in patients with advanced nsclc with egfr ins20. biological analysis will be performed on circulating tumor deoxyribonucleic acid (ctdna) at the time of disease progression and on tumor tissue at the time of disease progression when available. * ctdna : the extraction of the ctdna will be performed in an automated way with the promega rsc lv cfdna kit on maxwell platform. sequencing will be performed on nextseq500 platform with a panel of 208 genes (including 190 genes with full coverage of coding regions, and 11 genes with coverage of introns involved in translocations) covering 800 kpb and at a target depth of 8000 x. * tissue : deoxyribonucleic acid (dna) next generation sequencing (ngs) will be performed on tumor biopsy (10 slides of 5 microns) . samples will be sent for centralized analysis to centre de recherche en cancérologie de marseille (crcm), 27 bd lei roure, 13009 marseille (prof. tomasini and gwenaël lumet), and will be stored at centre de ressources biologiques de l'assistance publique hôpitaux de marseille (crb ap-hm), 264 rue saint-pierre, 13005 marseille.

Eligibility criteria:
inclusion criteria: * all patients with advanced nsclc with egfr ins20 receiving amivantamab as monotherapy in france under atu or eap; * age ≥ 18 years; * histologically confirmed advanced nsclc (metastatic or locally advanced unresectable and not suitable for definitive radiotherapy) with egfr ins20; * patients included will be required to sign an informed consent form to collect blood samples (liquid biopsy) and tissue biopsy when available at progression on amivantamab; * confirmed progression on amivantamab according to recist 1.1; * patient enrolled in the french national health insurance program or with a third- party payer. exclusion criteria: * patients receiving amivantamab in combination with another therapy; * patients who do not consent to liquid biopsy at progression.
study to assess the pharmacokinetics, safety and tolerability of aztreonam-avibactam in healthy chinese participants.

Conditions: Healthy

Summary: a phase 1, single center, single arm, open-label study to assess the pk, safety and tolerability of aztreonam-avibactam after single and repeated iv infusion of doses in healthy chinese participants.


Eligibility criteria:
inclusion criteria: * healthy chinese male and female participants * no clinical relevant abnormalities * willing and able to comply with all study procedures * bmi:17.5-30.5 * sign informed consent exclusion criteria: * any clinical significant illness * history of alcohol abuse * use within 14 days prior the first study dose * cl\>80ml/min * abnormal vital signs, such 12-ecg, blood pressure and pulse rate * blood donation within 60days * history of hiv, hbsag, hbcab, hcvab * other medical or psychiatric may inappropriate for the study

Keywords: no clinically relevant abnormalities
evaluation of intra-articular injection of autologous protein solution ("aps(tm)") for the treatment of osteoarthritis (oa)

Conditions: Gonarthrosis; Knee Osteoarthritis; Osteoarthritis

Summary: this prospective single-center study will evaluate the safety and tolerability of a single dose of "aps(tm)" treated patients with oa of the knee who have failed conservative oa therapy. the study will also evaluate efficacy by assessing patient pain and functionality.


Eligibility criteria:
eligibility criteria: * male or female ≥40 years. * willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions. * a standing radiograph of the knee showing a kellgren grade of 2 or 3 * frequency of knee pain on most days over the last month. * diagnosis of unilateral knee oa * body mass index (bmi) ≤40 kg/m2. * failed conservative oa therapy. * signed an independent ethics committee (iec)-approved informed consent form (icf). * willingness to abstain from the use of topical pain therapies, intra-articular corticosteroids, and viscosupplementation during the study. * willingness to abstain from systemic pain medications except rescue medication.

Keywords: autologous protein solution aps osteoarthritis injection
effect of four-week wellness program on work engagement burnout and sleep in a healthcare organization (webs)

Conditions: Sleep; Burnout; Work Engagement

Summary: the goal of this clinical trial is to learn if having a 4-week heartfulness meditation program in a healthcare organization would 1. decrease burnout 2. improve sleep and work engagement. researchers will compare : intervention group : participating in 4 weeks of heartfulness meditation with control group: receiving no intervention responses to the utrecht work engagement scale (uwes), bergen insomnia scale (bis) and two burnout questions will be compared between the study groups at the beginning and end of the intervention period.

the study is an 8-week single-center prospective, randomized, crossover study among healthcare workers in the wellspan health system. all participants were asked to answer two demographic questions and responses to the utrecht work engagement scale (uwes), and bergen insomnia scale (bis), two burnout questions were requested for a baseline. participants were randomized to two groups. one of the groups would undergo the intervention first, which comprised receiving an orientation session regarding the study, attending at least once weekly didactic sessions on zoom, and participating in morning and evening meditation for ten to fifteen minutes daily. the duration of the intervention period was four weeks. during this time, the control group would not be undergoing any intervention. after four weeks, both groups completed the original questionnaire again followed by a 2 week washout period. this was followed by a crossover, allowing the second group to undergo the intervention for four weeks. after four weeks, the final survey was sent to all participants again.

Eligibility criteria:
inclusion criteria: * age above 18 and willing to participate * able to understand the english language as the instructions were in english exclusion criteria: * not able to understand english language

Keywords: heartfulness meditation work enagement sleep burnout
electro flo 5000 and vest therapy

Conditions: Cystic Fibrosis

Summary: it is the goal of the proposed study to compare the efficacy, as assessed primarily by sputum weight, of these two different devices (the electroflo 500 and vest therapy) for airway clearance (ac) in cf patients with mild to moderate lung disease, who have stable lung health and perform ac at home as part of their routine therapeutic regimen.


Eligibility criteria:
inclusion criteria: 1. diagnosis of cf established by standard criteria (sweat chloride \> 60 mmol/l and/or two alleles affected by gene mutations know to be associated with cf). 2. age older than 12 years. 3. known to consistently produce sputum. 4. currently on a home therapeutic regimen that includes some form of ac performed at least 2 times daily. 5. fvc and fev1 \> 40%-predicted, and with stable lung function (no greater than a 10% variation in lung function parameters over the preceding 3 months). exclusion criteria: 1. hospitalization for cf pulmonary complications in the 2 months preceding enrollment. 2. hemoptysis \> 60 cc in a single episode in the 4 weeks preceding enrollment. 3. chronic chest pain. 4. participation in another interventional clinical trial in the previous 30 days. -
development and prevention of severe heart disease in systemic sclerosis

Conditions: Systemic Sclerosis; Cardiac Diseases; Heart Block; Cardiac Arrhythmia; Congestive Heart Failure

Summary: systemic sclerosis is an orphan, multiorgan disease affecting the connective tissue of the skin and all internal organs. cardiac involvement, mainly characterised by small intramyocardial coronary artery involvement and myocardial fibrosis, can cause the development of impaired diastolic ventricular filling, cardiac blocks and ventricular arrhythmias, and can ensue in congestive heart failure and sudden death. until now, no drug has been proven to have a therapeutic effect on ssc myocardial disease on an evidence-based level. short-term trials and retrospective studies have suggested a favourable and protective effect of calcium channel blockers and angiotensin converting enzyme inhibitors in patients with myocardial involvement. however, no data are presently available on the prevention and treatment of severe heart disease. this observational trial is part of the collaborative project "desscipher", one out of five observational trials to decipher the optimal management of systemic sclerosis. aim of this observational trial is to assess the efficacy and safety of calcium channel blockers and angiotensin converting enzyme inhibitors in asymptomatic ssc patients with cardiac involvement.


Eligibility criteria:
inclusion criteria: * juvenile and adult systemic sclerosis patients, with diagnosis according to the ssc acr/eular criteria or the pres/acr/eular juvenile ssc criteria respectively * asymptomatic (for cardiac disease) systemic sclerosis patients at risk for severe heart disease with at least one of the following risk factors: male sex and/or dlco lower than 80% and/or spap \> 30 mmhg and/or synovitis and/or joint contractures and/or digital ulcers and/or proteinuria. asymptomatic for cardiac disease is defined by patients without dyspnea nyha \>/= ii, without palpitations and without bilateral leg edema. exclusion criteria: * any significant pulmonary parenchymal (fvc \ 40 mmhg), gastrointestinal (malabsorption syndrome or paralytic ileus) or renal (serum creatinine level \>1.2 mg/dl, dialysis or previous scleroderma renal crisis) involvement * patients with dyspnea class nyha \>/= ii * patients with palpitations * patients with bilateral leg edema.